TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
LTR Pharma Limited ( (AU:LTP) ) has issued an update.
LTR Pharma Limited announced its 2025 Annual General Meeting, highlighting its ongoing efforts to expand its market presence and product pipeline. The company’s focus on strategic partnerships and regulatory advancements aims to enhance its global footprint and deliver patient-centric treatments, reflecting its commitment to improving quality of life for patients with significant medical needs.
More about LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company focused on delivering innovative therapies for unmet medical needs through its proprietary intranasal drug delivery platform. The company has commercialized its rapid-acting treatment technology in Australia and is expanding into the US and other key markets. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for erectile dysfunction, and it is developing OROFLOW for Oesophageal Motility Disorders.
Average Trading Volume: 880,428
Technical Sentiment Signal: Buy
Current Market Cap: A$97.16M
See more insights into LTP stock on TipRanks’ Stock Analysis page.